|
|
|
Insider
Information: |
Isaly Samuel D |
Relationship: |
10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
36 |
|
Direct
Shares |
1,096,936 |
|
Indirect Shares
|
77,548,174 |
|
|
Direct
Value |
$110 |
|
|
Indirect Value
|
$819,338,535 |
|
|
Total
Shares |
78,645,110 |
|
|
Total
Value |
$819,338,645 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
4
|
0
|
Stock
price went up :
|
4
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
4.0
|
0.0
|
Percentage
Gain/Loss : |
54.4%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
American Cryostem Corporation |
CRYO |
Director, 10% Owner |
2005-07-13 |
1,096,936 |
2005-07-13 |
1,231,936 |
Premium* |
|
Volcano Corp |
VOLC |
Director |
2006-06-20 |
0 |
2006-06-20 |
195,705 |
Premium* |
|
Aryx Therapeutics Inc |
ARYX |
10% Owner |
2007-11-13 |
0 |
2009-05-22 |
1,340,139 |
Premium* |
|
Albireo Pharma Inc |
ALBO |
Director |
2008-02-12 |
0 |
2009-06-10 |
1,485,904 |
Premium* |
|
Athersys Inc (New) |
ATHX |
10% Owner |
2008-05-21 |
0 |
2011-04-26 |
15,250 |
Premium* |
|
Nxstage Medical, Inc. |
NXTM |
Director |
2010-12-09 |
0 |
2010-12-09 |
2,690,476 |
Premium* |
|
Kun Run Biotechnology Inc |
KURU |
10% Owner |
|
0 |
2010-04-30 |
5,228,758 |
Premium* |
|
Anthera Pharmaceuticals Inc |
ANTH |
Director |
2010-09-30 |
0 |
2013-01-30 |
7,462,000 |
Premium* |
|
Amarin Corp Plc |
AMRN |
Director |
|
0 |
2012-09-04 |
5,700 |
Premium* |
|
Pacira Pharmaceuticals, Inc. |
PCRX |
10% Owner |
|
0 |
2012-03-12 |
2,446,000 |
Premium* |
|
Chemocentryx, Inc. |
CCXI |
10% Owner |
2012-02-13 |
0 |
2012-02-13 |
908,509 |
Premium* |
|
Supernus Pharmaceuticals Inc |
SUPN |
Director, 10% Owner |
2012-05-04 |
0 |
2012-05-04 |
297,815 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
|
0 |
2015-02-03 |
1,267,000 |
Premium* |
|
Acceleron Pharma Inc |
XLRN |
Former 10% Owner |
2013-09-24 |
0 |
2013-09-24 |
576,889 |
Premium* |
|
Relypsa Inc |
RLYP |
10% Owner |
2013-11-20 |
0 |
2016-07-25 |
3,356,400 |
Premium* |
|
Roka Bioscience, Inc. |
ROKA |
10% Owner |
|
0 |
2017-10-03 |
0 |
Premium* |
|
Loxo Oncology, Inc. |
LOXO |
Director |
2014-08-06 |
0 |
2017-12-08 |
941,000 |
Premium* |
|
Otonomy, Inc. |
OTIC |
Director |
2014-08-18 |
0 |
2015-11-30 |
1,850,094 |
Premium* |
|
Sientra, Inc. |
SIEN |
10% Owner |
|
0 |
2015-10-12 |
17,100 |
Premium* |
|
Pieris Pharmaceuticals, Inc. |
PIRS |
10% Owner |
|
0 |
2018-01-03 |
49,270 |
Premium* |
|
Glaukos Corp |
GKOS |
Director |
2015-06-30 |
0 |
2017-09-05 |
7,895 |
Premium* |
|
Dimension Therapeutics, Inc. |
DMTX |
Director, 10% Owner |
2015-10-27 |
0 |
2015-10-27 |
5,397,698 |
Premium* |
|
Adaptimmune Therapeutics PLC |
ADAP |
Director |
|
0 |
2017-03-27 |
6,149,377 |
Premium* |
|
Viewray, Inc. |
VRAY |
Director, 10% Owner |
|
0 |
2017-01-18 |
89,225 |
Premium* |
|
Aeglea Biotherapeutics, Inc. |
AGLE |
10% Owner |
|
0 |
2017-02-21 |
1,469,524 |
Premium* |
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2016-05-11 |
0 |
2016-05-11 |
2,662,180 |
Premium* |
|
Corvus Pharmaceuticals, Inc. |
CRVS |
Director, 10% Owner |
2016-05-18 |
0 |
2016-06-24 |
5,379,349 |
Premium* |
|
Selecta Biosciences Inc |
SELB |
Director, 10% Owner |
|
0 |
2016-06-27 |
1,825,415 |
Premium* |
|
Steadymed Ltd. |
STDY |
10% Owner |
|
0 |
2017-04-25 |
2,123,098 |
Premium* |
|
Nabriva Therapeutics AG |
NBRV |
Director, 10% Owner |
|
0 |
2016-12-30 |
391,960 |
Premium* |
|
Aadi Bioscience, Inc |
AADI |
Director, 10% Owner |
2017-03-15 |
0 |
2017-03-15 |
4,416,446 |
Premium* |
|
Cti Biopharma Corporation |
CTIC |
10% Owner |
2017-06-13 |
0 |
2017-06-13 |
5,000,000 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
Director, 10% Owner |
2017-07-24 |
0 |
2017-07-24 |
3,298,516 |
Premium* |
|
Kala Pharmaceuticals, Inc. |
KALA |
10% Owner |
2017-07-25 |
0 |
2018-01-12 |
2,692,715 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2017-11-21 |
0 |
2017-11-21 |
3,409,865 |
Premium* |
|
X4 Pharmaceuticals Inc |
XFOR |
10% Owner |
2017-11-20 |
0 |
2017-11-20 |
1,868,966 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
248 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 10
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CRYO |
American Cryostem Corpora... |
10% Owner |
|
2005-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,096,936 |
|
- |
|
CTIC |
Cti Biopharma Corporation |
10% Owner |
|
2017-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
5,000,000 |
5,000,000 |
0 |
- |
|
DMTX |
Dimension Therapeutics, I... |
Director |
|
2015-10-27 |
4 |
B |
$13.00 |
$2,600,000 |
I/I |
200,000 |
5,397,698 |
2.25 |
- |
|
DMTX |
Dimension Therapeutics, I... |
Director |
|
2015-10-27 |
4 |
A |
$0.00 |
$0 |
I/I |
5,197,698 |
5,197,698 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2015-06-30 |
4 |
D |
$18.00 |
$211,212 |
I/I |
(11,734) |
27,344 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2015-06-30 |
4 |
OE |
$0.00 |
$0 |
I/I |
27,607 |
27,455 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2015-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
2,882,064 |
27,194 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2016-08-03 |
4 |
S |
$30.59 |
$13,000,750 |
I/I |
(425,000) |
23,334 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2016-08-10 |
4 |
S |
$33.77 |
$3,982,766 |
I/I |
(117,938) |
22,221 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2016-08-11 |
4 |
S |
$33.63 |
$5,411,067 |
I/I |
(160,900) |
20,703 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2016-08-12 |
4 |
S |
$33.72 |
$475,452 |
I/I |
(14,100) |
20,570 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-03-03 |
4 |
S |
$47.05 |
$2,624,073 |
I/I |
(55,772) |
20,044 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-03-10 |
4 |
S |
$45.98 |
$4,461,347 |
I/I |
(97,028) |
19,129 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-03-13 |
4 |
S |
$45.30 |
$9,577,454 |
I/I |
(211,410) |
17,134 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-03-14 |
4 |
S |
$44.54 |
$3,300,414 |
I/I |
(74,100) |
16,435 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-08-15 |
4 |
S |
$38.29 |
$1,244,425 |
I/I |
(32,500) |
16,128 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-08-16 |
4 |
S |
$38.01 |
$2,492,696 |
I/I |
(65,580) |
15,509 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-08-17 |
4 |
S |
$37.85 |
$8,588,922 |
I/I |
(226,920) |
13,369 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-08-31 |
4 |
S |
$37.82 |
$1,698,950 |
I/I |
(44,922) |
12,945 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-09-01 |
4 |
S |
$37.72 |
$4,152,142 |
I/I |
(110,078) |
11,907 |
0 |
- |
|
GKOS |
Glaukos Corp |
Director |
|
2017-09-05 |
4 |
S |
$37.94 |
$16,621,730 |
I/I |
(425,200) |
7,895 |
0 |
- |
|
KALA |
Kala Pharmaceuticals, Inc... |
See Remarks |
|
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,055,946 |
2,055,946 |
0 |
- |
|
KALA |
Kala Pharmaceuticals, Inc... |
See Remarks |
|
2017-07-25 |
4 |
B |
$15.00 |
$4,789,995 |
I/I |
319,333 |
2,375,279 |
1.5 |
- |
|
KALA |
Kala Pharmaceuticals, Inc... |
10% Owner |
|
2018-01-10 |
4 |
B |
$12.83 |
$2,185,437 |
I/I |
170,338 |
2,622,569 |
1.5 |
- |
|
KALA |
Kala Pharmaceuticals, Inc... |
10% Owner |
|
2018-01-11 |
4 |
B |
$13.65 |
$569,205 |
I/I |
41,700 |
2,664,269 |
1.5 |
- |
|
248 Records found
|
|
Page 5 of 10 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|